1
|
Matsuura K, Nakada C, Mashio M, Narimatsu
T, Yoshimoto T, Tanigawa M, Tsukamoto Y, Hijiya N, Takeuchi I,
Nomura T, et al: Downregulation of SAV1 plays a role in
pathogenesis of high-grade clear cell renal cell carcinoma. BMC
Cancer. 11:5232011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Miyamoto H, Miller JS, Fajardo DA, Lee TK,
Netto GJ and Epstein JI: Non-invasive papillary urothelial
neoplasms: The 2004 WHO/ISUP classification system. Pathol Int.
60:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
3
|
Montironi R, Santinelli A, Pomante R,
Mazzucchelli R, Colanzi P, Filho AL and Scarpelli M: Morphometric
index of adult renal cell carcinoma. Comparison with the Fuhrman
grading system. Virchows Arch. 437:82–89. 2000. View Article : Google Scholar : PubMed/NCBI
|
4
|
Cindolo L, Patard JJ, Chiodini P, Schips
L, Ficarra V, Tostain J, de La Taille A, Altieri V, Lobel B,
Zigeuner RE, et al: Comparison of predictive accuracy of four
prognostic models for nonmetastatic renal cell carcinoma after
nephrectomy: A multicenter European study. Cancer. 104:1362–1371.
2005. View Article : Google Scholar : PubMed/NCBI
|
5
|
Jiang Z, Chu PG, Woda BA, Liu Q, Balaji
KC, Rock KL and Wu CL: Combination of quantitative IMP3 and tumor
stage: A new system to predict metastasis for patients with
localized renal cell carcinomas. Clin Cancer Res. 14:5579–5584.
2008. View Article : Google Scholar : PubMed/NCBI
|
6
|
Kim SP, Alt AL, Weight CJ, Costello BA,
Cheville JC, Lohse C, Allmer C and Leibovich BC: Independent
validation of the 2010 American Joint Committee On Cancer TNM
classification for renal cell carcinoma: Results from a large,
single institution cohort. J Urol. 185:2035–2039. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Lu D, Wu Y, Wang Y, Ren F, Wang D, Su F,
Zhang Y, Yang X, Jin G, Hao X, et al: CREPT accelerates
tumorigenesis by regulating the transcription of cell-cycle-related
genes. Cancer Cell. 21:92–104. 2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
Ma J, Ren Y, Zhang L, Kong X, Wang T, Shi
Y and Bu R: Knocking-down of CREPT prohibits the progression of
oral squamous cell carcinoma and suppresses cyclin D1 and c-Myc
expression. PLos One. 12:e1743092017.
|
9
|
Liang Z, Feng Q, Xu L, Li S and Zhou L:
CREPT regulated by miR-138 promotes breast cancer progression.
Biochem Biophys Res Commun. 493:263–269. 2017. View Article : Google Scholar : PubMed/NCBI
|
10
|
Zheng G, Li W, Zuo B, Guo Z, Xi W, Wei M,
Chen P, Wen W and Yang AG: High expression of CREPT promotes tumor
growth and is correlated with poor prognosis in colorectal cancer.
Biochem Biophys Res Commun. 480:436–442. 2016. View Article : Google Scholar : PubMed/NCBI
|
11
|
Liu T, Li WM, Wang WP, Sun Y, Ni YF, Xing
H, Xia JH, Wang XJ, Zhang ZP and Li XF: Inhibiting CREPT reduces
the proliferation and migration of non-small cell lung cancer cells
by down-regulating cell cycle related protein. Am J Transl Res.
8:2097–2113. 2016.PubMed/NCBI
|
12
|
Ren F, Wang R, Zhang Y, Liu C, Wang Y, Hu
J, Zhang L and Chang Z: Characterization of a monoclonal antibody
against CREPT, a novel protein highly expressed in tumors. Monoclon
Antib Immunodiagn Immunother. 33:401–408. 2014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Mei K, Jin Z, Ren F, Wang Y, Chang Z and
Wang X: Structural basis for the recognition of RNA polymerase II
C-terminal domain by CREPT and p15RS. Sci China Life Sci.
57:97–106. 2014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Wang Y, Qiu H, Hu W, Li S and Yu J: RPRD1B
promotes tumor growth by accelerating the cell cycle in endometrial
cancer. Oncol Rep. 31:1389–1395. 2014. View Article : Google Scholar : PubMed/NCBI
|
15
|
Zhang Y, Liu C, Duan X, Ren F, Li S, Jin
Z, Wang Y, Feng Y, Liu Z and Chang Z: CREPT/RPRD1B, a recently
identified novel protein highly expressed in tumors, enhances the
β-catenin. TCF4 transcriptional activity in response to Wnt
signaling. J Biol Chem. 289:22589–22599. 2014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Fisseler-Eckhoff A: New TNM classification
of malignant lung tumors 2009 from a pathology perspective.
Pathologe. 30 (Suppl 2):S193–S199. 2009.(In German). View Article : Google Scholar
|
17
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
18
|
Sinn BV, von Minckwitz G, Denkert C,
Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G,
Belau A, Thommsen C, et al: Evaluation of Mucin-1 protein and mRNA
expression as prognostic and predictive markers after neoadjuvant
chemotherapy for breast cancer. Ann Oncol. 24:2316–2324. 2013.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: A convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
20
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Delahunt B, Sika-Paotonu D, Bethwaite PB,
William Jordan T, Magi-Galluzzi C, Zhou M, Samaratunga H and
Srigley JR: Grading of clear cell renal cell carcinoma should be
based on nucleolar prominence. Am J Surg Pathol. 35:1134–1139.
2011. View Article : Google Scholar : PubMed/NCBI
|
22
|
Erdoğan F, Demirel A and Polat O:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Int J Clin Pract. 58:333–336. 2004. View Article : Google Scholar : PubMed/NCBI
|
23
|
Xu J, Huang B, Li S, Zhang X, Xie T and Xu
Y: Knockdown of LETM1 inhibits proliferation and metastasis of
human renal cell carcinoma cells. Oncol Lett. 16:6377–6382.
2018.PubMed/NCBI
|
24
|
Wang Y, Li G, Wan F, Dai B and Ye D:
Prognostic value of D-lactate dehydrogenase in patients with clear
cell renal cell carcinoma. Oncol Lett. 16:866–874. 2018.PubMed/NCBI
|
25
|
Chen P, Zhao L, Pan X, Jin L, Lin C, Xu W,
Xu J, Guan X, Wu X, Wang Y, et al: Tumor suppressor microRNA-136-5p
regulates the cellular function of renal cell carcinoma. Oncol
Lett. 15:5995–6002. 2018.PubMed/NCBI
|
26
|
Zhang XL, Xu G, Zhou Y and Yan JJ:
MicroRNA-183 promotes the proliferation and metastasis of renal
cell carcinoma through targeting Dickkopf-related protein 3. Oncol
Lett. 15:6003–6008. 2018.PubMed/NCBI
|
27
|
Li J, Smith AR, Marquez RT, Li J, Li K,
Lan L, Wu X, Zhao L, Ren F, Wang Y, et al: MicroRNA-383 acts as a
tumor suppressor in colorectal cancer by modulating CREPT/RPRD1B
expression. Mol Carcinog. 57:1408–1420. 2018. View Article : Google Scholar : PubMed/NCBI
|
28
|
Kuang YS, Wang Y, Ding LD, Yang L, Wang Y,
Liu SH, Zhu BT, Wang XN, Liu HY, Li J, et al: Overexpression of
CREPT confers colorectal cancer sensitivity to fluorouracil. World
J Gastroenterol. 24:475–483. 2018. View Article : Google Scholar : PubMed/NCBI
|
29
|
Kim JK and Diehl JA: Nuclear cyclin D1: An
oncogenic driver in human cancer. J Cell Physiol. 220:292–296.
2009. View Article : Google Scholar : PubMed/NCBI
|
30
|
Nojima H: G1 and S-phase checkpoints,
chromosome instability, and cancer. Methods Mol Biol. 280:3–49.
2004.PubMed/NCBI
|
31
|
Massague J: G1 cell-cycle control and
cancer. Nature. 432:298–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
32
|
Liu Z, Fu Q, Lv J, Wang F and Ding K:
Prognostic implication of p27Kip1, Skp2 and Cks1 expression in
renal cell carcinoma: A tissue microarray study. J Exp Clin Cancer
Res. 27:512008. View Article : Google Scholar : PubMed/NCBI
|
33
|
Lima MS, Pereira RA, Costa RS, Tucci S,
Dantas M, Muglia VF, Ravinal RC and Barros-Silva GE: The prognostic
value of cyclin D1 in renal cell carcinoma. Int Urol Nephrol.
46:905–913. 2014. View Article : Google Scholar : PubMed/NCBI
|
34
|
Sun M, Si G, Sun HS and Si FC: Inhibition
of CREPT restrains gastric cancer growth by regulation of cycle
arrest, migration and apoptosis via ROS-regulated p53 pathway.
Biochem Biophys Res Commun. 496:1183–1190. 2018. View Article : Google Scholar : PubMed/NCBI
|